Event Type
Disclosure
Mandatory
Variant
8-K
. Material Agreements. On October 1, 2025, the board of directors (the “Board”) of Kairos Pharma, Ltd., a Delaware Corporation (“Kairos” or the “Company”), appr
, including Exhibit 99.1. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Novation Agreement between Kairos Pharma, Ltd.,